Skip to main content

Advertisement

SpringerLink
Log in

Managing the Primary Tumor with Unresectable Synchronous Colorectal Metastases

  • Colorectal Cancer Hepatic Metastases (MA Choti, Section Editor)
  • Published:
Current Colorectal Cancer Reports

Abstract

Colorectal cancer is the third most commonly diagnosed cancer in men and the second most common in women. Approximately 20 % of patients with colorectal cancer are found to have metastatic disease (stage IV) at the time of diagnosis. A multidisciplinary approach provides the best chance for a potentially curative option in selected patients with metastases, but in most patients, the metastases are unresectable. The treatment strategy for this entity is not fully established, especially regarding whether and when the primary tumor should be resected. In this manuscript, we review current evidence regarding approaches to the primary tumor in patients with unresectable synchronous metastases from colorectal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  PubMed  Google Scholar 

  2. Kohler BA, Sherman RL, Howlader N, et al. Annual Report to the Nation on the Status of Cancer, 1975–2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J Natl Cancer Inst. 2015;107:djv048.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  PubMed  Google Scholar 

  4. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254–62.

    Article  CAS  PubMed  Google Scholar 

  5. Mise Y, Zimmitti G, Shindoh J, et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol. 2015;22:834–42. Retrospective study revealing that RAS mutation status may predict response to chemotherapy. In this study, authors reported 59% major pathologic response rate in colorectal liver metastases patients with wild-type RAS.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–9.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006;141:460–6. discussion 466–467.

    Article  PubMed  Google Scholar 

  8. Tepper JEOCM, Hollis D, et al. Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. J Clin Oncol. 2003;21:3623–8.

    Article  CAS  PubMed  Google Scholar 

  9. Kim AWFL, Warren WH, et al. Repeat pulmonary resection for metachronous colorectal carcinoma is beneficial. Surgery. 2008;144:712–7.

    Article  PubMed  Google Scholar 

  10. Ogata Y, Matono K, Hayashi A, et al. Repeat pulmonary resection for isolated recurrent lung metastases yields results comparable to those after first pulmonary resection in colorectal cancer. World J Surg. 2005;29:363–8.

    Article  PubMed  Google Scholar 

  11. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007;84:324–38.

    Article  PubMed  Google Scholar 

  12. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–25.

  13. Tanaka K, Shimada H, Ueda M, Matsuo K, Endo I, Togo S. Long-term characteristics of 5-year survivors after liver resection for colorectal metastases. Ann Surg Oncol. 2007;14:1336–46.

    Article  PubMed  Google Scholar 

  14. Lee WS, Yun SH, Chun HK, et al. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis. 2007;22:699–704.

    Article  PubMed  Google Scholar 

  15. Sakamoto T, Tsubota N, Iwanaga K, et al. Pulmonary resection for metastases from colorectal cancer. Chest. 2001;119:1069–72.

    Article  CAS  PubMed  Google Scholar 

  16. Adam R, de Gramont A, Figueras J, et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015;41:729–41.

    Article  PubMed  Google Scholar 

  17. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18. discussion 318–321.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Shimizu Y, Yasui K, Sano T, et al. Treatment strategy for synchronous metastases of colorectal cancer: is hepatic resection after an observation interval appropriate? Langenbecks Arch Surg. 2007;392:535–8.

    Article  PubMed  Google Scholar 

  20. Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7:109–15. discussion 116–107.

    Article  PubMed  Google Scholar 

  21. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57. discussion 657–648.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677–83.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol. 2005;23:8490–9.

    Article  PubMed  Google Scholar 

  24. Benson 3rd AB, Venook AP, Bekaii-Saab T, et al. Colon cancer, version 3.2014. J Natl Compr Canc Netw. 2014;12:1028–59.

    CAS  PubMed  Google Scholar 

  25. Anwar S, Peter MB, Dent J, Scott NA. Palliative excisional surgery for primary colorectal cancer in patients with incurable metastatic disease. Is there a survival benefit? A systematic review. Colorectal Dis. 2012;14:920–30. A systematic review which include 21 non-randomized trials evaluating palliative resection of stage IV colorectal cancer with unresectable metastases. Multivariate analysis indicated that tumor burden and performance status are both major independent prognostic variables.

    Article  CAS  PubMed  Google Scholar 

  26. Berri RN, Abdalla EK. Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep. 2009;11:200–8.

    Article  PubMed  Google Scholar 

  27. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829–35.

    Article  PubMed  Google Scholar 

  28. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23:9243–9.

    Article  CAS  PubMed  Google Scholar 

  29. Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005;16:425–9.

    Article  CAS  PubMed  Google Scholar 

  30. Barone C, Nuzzo G, Cassano A, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97:1035–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ychou M, Viret F, Kramar A, et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol. 2008;62:195–201.

    Article  CAS  PubMed  Google Scholar 

  32. Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249:420–5.

    Article  PubMed  Google Scholar 

  33. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670–6.

    Article  CAS  PubMed  Google Scholar 

  34. Wein A, Riedel C, Kockerling F, et al. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol. 2001;12:1721–7.

    Article  CAS  PubMed  Google Scholar 

  35. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311–9.

    Article  CAS  PubMed  Google Scholar 

  36. Gruenberger T, Bridgewater J, Chau I, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26:702–8. A multicenter phase II trial comparing bevacizumab plus mFOLFOX-6 with bevacizumab plus FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer. Authors reported higher response rate and resection rate in bevacizumab-FOLFOXIRI group.

    Article  CAS  PubMed  Google Scholar 

  37. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94:798–805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Huiskens J, van Gulik TM, van Lienden KP, et al. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer. 2015;15:365. On-going randomised phase III trial comparing chemotherapy regimens in RAS wild type tumors and RAS mutant tumors of patients with unresectable liver metastasis from colorectal cancer.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–72.

    Article  CAS  PubMed  Google Scholar 

  40. Bilchik AJ, Poston G, Curley SA, et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol. 2005;23:9073–8.

    Article  CAS  PubMed  Google Scholar 

  41. Kishi Y, Zorzi D, Contreras CM, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010;17:2870–6.

    Article  PubMed  Google Scholar 

  42. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761–7.

    Article  PubMed  Google Scholar 

  44. Chun YS, Laurent A, Maru D, Vauthey JN. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol. 2009;10:278–86.

    Article  CAS  PubMed  Google Scholar 

  45. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

    Article  CAS  PubMed  Google Scholar 

  46. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–5.

    Article  CAS  PubMed  Google Scholar 

  47. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439–42.

    Article  CAS  PubMed  Google Scholar 

  48. Thornton AD, Ravn P, Winslet M, Chester K. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg. 2006;93:1456–63.

    Article  CAS  PubMed  Google Scholar 

  49. Roman CD, Choy H, Nanney L, et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res. 2002;105:43–7.

    Article  CAS  PubMed  Google Scholar 

  50. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20:1842–7.

    Article  PubMed  Google Scholar 

  51. Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14:862–70.

    Article  CAS  PubMed  Google Scholar 

  52. Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep. 2012;14:277–84.

    Article  CAS  PubMed  Google Scholar 

  53. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol. 2006;24:668–74.

    Article  CAS  PubMed  Google Scholar 

  54. Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513–8. A pilot study evaluated efficacy of neoadjuvant chemotherapy without routine use of radiation in stage II or III rectal cancer. Authors reported that all patients who completed six cycles of FOLOFX in neoadjuvant setting showed regression, and the pathologic complete response rate was reported to be 25%.

    Article  CAS  PubMed  Google Scholar 

  55. Gervaz P, Rubbia-Brandt L, Andres A, et al. Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. Ann Surg Oncol. 2010;17:2714–9.

    Article  PubMed  Google Scholar 

  56. Ruo L, Gougoutas C, Paty PB, et al. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg. 2003;196:722–8.

    Article  PubMed  Google Scholar 

  57. Galizia G, Lieto E, Orditura M, et al. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg. 2008;143:352–8. discussion 358.

    Article  PubMed  Google Scholar 

  58. Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol. 2008;19:1829–35.

    Article  CAS  PubMed  Google Scholar 

  59. Stillwell AP, Buettner PG, Siu SK, et al. Predictors of postoperative mortality, morbidity, and long-term survival after palliative resection in patients with colorectal cancer. Dis Colon Rectum. 2011;54:535–44.

    Article  PubMed  Google Scholar 

  60. Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27:3379–84.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Seo GJ, Park JW, Yoo SB, et al. Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer. J Surg Oncol. 2010;102:94–9.

    Article  PubMed  Google Scholar 

  62. McCahill LE, Yothers G, Sharif S, et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol. 2012;30:3223–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Ballian N, Mahvi DM, Kennedy GD. Colonoscopic findings and tumor site do not predict bowel obstruction during medical treatment of stage IV colorectal cancer. Oncologist. 2009;14:580–5.

    Article  PubMed  Google Scholar 

  64. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–9.

    Article  CAS  PubMed  Google Scholar 

  65. Venderbosch S, de Wilt JH, Teerenstra S, et al. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol. 2011;18:3252–60.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Karoui M, Roudot-Thoraval F, Mesli F, et al. Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study. Dis Colon Rectum. 2011;54:930–8.

    Article  PubMed  Google Scholar 

  67. Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol. 2005;12:637–45.

    Article  PubMed  Google Scholar 

  68. Clancy C, Burke JP, Barry M, et al. A meta-analysis to determine the effect of primary tumor resection for stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg Oncol. 2014;21:3900–8. A meta-analysis which showed resection of the primary tumor in stage IV colorectal cancer patients with unresectable metastasis. Significant cross-study heterogeneity and significant selection bias were pointed out by the authors.

    Article  PubMed  Google Scholar 

  69. Faron M, Pignon JP, Malka D, et al. Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. Eur J Cancer. 2015;51:166–76. A pooled analysis of 4 retrospective studies comparing chemotherapy regimens, which showed improved survival associated with upfront surgical resection of primary tumor. Surgical resections were performed prior to trial entry.

    Article  PubMed  Google Scholar 

  70. Scoggins CR, Meszoely IM, Blanke CD, et al. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol. 1999;6:651–7.

    Article  CAS  PubMed  Google Scholar 

  71. Benoist S, Pautrat K, Mitry E, et al. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg. 2005;92:1155–60.

    Article  CAS  PubMed  Google Scholar 

  72. Slesser AA, Khan F, Chau I, et al. The effect of a primary tumour resection on the progression of synchronous colorectal liver metastases: an exploratory study. Eur J Surg Oncol. 2015;41:484–92. Retrospective analysis of patients with colorectal liver metastases evaluating primary tumor resection. Authors reported that an upfront primary tumor resection significantly affected progressive disease, and did not improve overall survival.

    Article  CAS  PubMed  Google Scholar 

  73. Cirocchi R, Trastulli S, Abraha I, et al. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev. 2012;8:CD008997.

    PubMed  Google Scholar 

  74. Alawadi Z PU, Kao L, Hu C, Bailey C, You Y, Chang GJ. Comparative effectiveness of primary tumor resection in metastatic colon cancer: an instrumental variable analysis. Society of Surgical Oncology 2015, Abstract presentation 2015. Abstract of an observation study of unresectable colon cancer patients identified in NCDB, presented at SSO 2015. After risk adjustment by Instrumental Variable analysis, there was no survival benefit with primary tumor resection at the 1 year landmark.

  75. t Lam-Boer J, Mol L, Verhoef C, et al. The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer—a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer. 2014;14:741. An on-going multicenter randomized phase III study evaluating the benefit of resection of the primary tumor in patients with synchronous metastatic colorectal cancer.

    Article  Google Scholar 

  76. Rahbari NN, Lordick F, Fink C, et al. Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS—a randomised controlled multicentre trial (ISRCTN30964555). BMC Cancer. 2012;12:142.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Cotte E, Villeneuve L, Passot G, et al. GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study. BMC Cancer. 2015;15:47. An on-going multicenter randomized phase III study evaluating the benefit of resection of the primary tumor in patients with synchronous metastaic rectal cancer.

  78. Hida K, Hasegawa S, Kinjo Y, et al. Open versus laparoscopic resection of primary tumor for incurable stage IV colorectal cancer: a large multicenter consecutive patients cohort study. Ann Surg. 2012;255:929–34.

    Article  PubMed  Google Scholar 

  79. van Hooft JE, van Halsema EE, Vanbiervliet G, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2014;46:990–1053.

    Article  PubMed  Google Scholar 

  80. Atukorale YN, Church JL, Hoggan BL et al. Self-expanding metallic stents for the management of emergency malignant large bowel obstruction: a systematic review. J Gastrointest Surg 2015. A systematic review evaluating the safety and effectiveness of self-expanding metallic stents (SEMS) for the managemency malignant colorectal obstruction in patients otherwise requiring multi-stage surgery. SEMS placement was assoicated with early progress to elective surgery with shorter hospital stays. Authors concluded that SEMS placement is a effective and safe bride-to-surgery.

  81. Kondo S, Fujita T, Nakanishi H, et al. Successful endoscopic stent placement as a bridge to surgery for colonic obstruction induced by bevacizumab-based chemotherapy. Clin J Gastroenterol. 2015;8:285–9.

    Article  PubMed  Google Scholar 

  82. La Mazza A, Fiori E, Schillaci A, et al. Endoscopic stenting for colorectal obstruction from unresectable ovarian and colorectal cancer: a bridge to surgery. Colorectal Dis. 2015;17:646–7.

    Article  PubMed  Google Scholar 

  83. Huang X, Lv B, Zhang S, Meng L. Preoperative colonic stents versus emergency surgery for acute left-sided malignant colonic obstruction: a meta-analysis. J Gastrointest Surg. 2014;18:584–91.

    Article  PubMed  Google Scholar 

  84. Sloothaak DA, van den Berg MW, Dijkgraaf MG, et al. Oncological outcome of malignant colonic obstruction in the Dutch Stent-In 2 trial. Br J Surg. 2014;101:1751–7.

    Article  CAS  PubMed  Google Scholar 

  85. Sebastian S, Johnston S, Geoghegan T, et al. Pooled analysis of the efficacy and safety of self-expanding metal stenting in malignant colorectal obstruction. Am J Gastroenterol. 2004;99:2051–7.

    Article  PubMed  Google Scholar 

  86. Yoon JY, Jung YS, Hong SP, et al. Clinical outcomes and risk factors for technical and clinical failures of self-expandable metal stent insertion for malignant colorectal obstruction. Gastrointest Endosc. 2011;74:858–68.

    Article  PubMed  Google Scholar 

  87. Liang TW, Sun Y, Wei YC, Yang DX. Palliative treatment of malignant colorectal obstruction caused by advanced malignancy: a self-expanding metallic stent or surgery? A system review and meta-analysis. Surg Today. 2014;44:22–33.

    Article  CAS  PubMed  Google Scholar 

  88. Small AJ, Coelho-Prabhu N, Baron TH. Endoscopic placement of self-expandable metal stents for malignant colonic obstruction: long-term outcomes and complication factors. Gastrointest Endosc. 2010;71:560–72.

    Article  PubMed  Google Scholar 

  89. van Halsema EE, van Hooft JE, Small AJ, et al. Perforation in colorectal stenting: a meta-analysis and a search for risk factors. Gastrointest Endosc. 2014;79:970–82. e977; quiz 983 e972, 983 e975.

    Article  PubMed  Google Scholar 

  90. Kimmey MB. Endoscopic methods (other than stents) for palliation of rectal carcinoma. J Gastrointest Surg. 2004;8:270–3.

    Article  PubMed  Google Scholar 

  91. Meisner S, Gonzalez-Huix F, Vandervoort JG, et al. Self-expandable metal stents for relieving malignant colorectal obstruction: short-term safety and efficacy within 30 days of stent procedure in 447 patients. Gastrointest Endosc. 2011;74:876–84.

    Article  PubMed  Google Scholar 

  92. Farouk R, Ratnaval CD, Monson JR, Lee PW. Staged delivery of Nd:YAG laser therapy for palliation of advanced rectal carcinoma. Dis Colon Rectum. 1997;40:156–60.

    Article  CAS  PubMed  Google Scholar 

  93. Courtney ED, Raja A, Leicester RJ. Eight years experience of high-powered endoscopic diode laser therapy for palliation of colorectal carcinoma. Dis Colon Rectum. 2005;48:845–50.

    Article  PubMed  Google Scholar 

  94. Mesko TW, Petrelli NJ, Rdriguez-Bigas M, Nava H. Endoscopic laser treatment for colorectal adenocarcinoma. Surg Oncol 1993;2:25–30.

  95. Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg. 2010;34:797–807.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MD Anderson Cancer Center, Department of Surgical Oncology, 1400 Pressler Street, FCT17.5028, Houston, TX, 77030, USA

    Naruhiko Ikoma & Miguel A. Rodriguez-Bigas

Authors
  1. Naruhiko Ikoma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miguel A. Rodriguez-Bigas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miguel A. Rodriguez-Bigas.

Ethics declarations

Conflict of Interest

Naruhiko Ikoma and Miguel A Rodriguez-Bigas declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Colorectal Cancer Hepatic Metastases

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ikoma, N., Rodriguez-Bigas, M.A. Managing the Primary Tumor with Unresectable Synchronous Colorectal Metastases. Curr Colorectal Cancer Rep 12, 170–179 (2016). https://doi.org/10.1007/s11888-016-0322-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-016-0322-9

Keywords

Search

Navigation